THE NEXT GENERATION OF DEALMAKING

The dealmaking landscape has shifted. Not only have we witnessed a change in its leaders, but many of them believe that medium sized biopharma companies are more active and innovative than their large pharma counterparts. Today, big pharma companies may even be seen tapping into biotech dealmaking leaders for their top posts.

What has caused this transition and what can we expect in the years ahead?

Do not miss out on Allicense 2014 to meet these new players and learn about current trends across the dynamic and exciting field of biopharma dealmaking.

Partners:

Twitter
LinkedIn
Blog

Join the conversation on Twitter: #Allicense2014

Syndax